Smruthi Organics Share News - Latest Updates, Live News & More

Latest news about Smruthi Organics

Smruthi Organics Schedules Board Meeting on May 13, 2026 to Approve Q4FY26 Audited Results and Dividend 5 days ago

Smruthi Organics Limited has scheduled a Board of Directors meeting on May 13, 2026, to approve audited financial results under Ind AS for the quarter and financial year ended March 31, 2026. The board will also consider recommending a dividend, if any, on equity shares for the financial year ending March 31, 2026. The company's trading window, closed since April 1, 2026, will remain shut until 48 hours after the declaration of results. The filing was made on May 6, 2026, under Regulation 29(1) of SEBI (LODR) Regulations, 2015.

Smruthi Organics Limited Files SEBI Compliance Certificate for Q4 FY26 Apr 07, 2026

Smruthi Organics Receives CEP Certificate from EDQM for Amlodipine Besilate Mar 09, 2026

Smruthi Organics Reports Q3 FY26 Results Following Board Meeting Approval Feb 16, 2026

Smruthi Organics Limited Schedules Board Meeting on February 13, 2026 for Q3FY26 Results Approval Feb 05, 2026

More news about Smruthi Organics

11Nov 25

Smruthi Organics Reports Robust Q2 Recovery with Rs 205.62 Crore Net Profit

Smruthi Organics Limited announced unaudited Q2 FY2026 results, showing a significant turnaround with a net profit of Rs 205.62 crore, compared to a loss of Rs 109.54 crore in Q1. Revenue from operations increased to Rs 3,159.52 crore. The API segment remains the major contributor with Rs 5,045.74 crore revenue for the half-year, while the formulations segment reported sales of Rs 21.48 crore but incurred a loss. Total assets stood at Rs 9,963.73 crore with total equity at Rs 7,080.85 crore as of September 30, 2025.

13Aug 25

Smruthi Organics Reports Net Loss of Rs 109.54 Lakhs in Q1

Smruthi Organics, a bulk drugs manufacturer, announced unaudited Q1 results showing a 30.36% year-over-year revenue decline to Rs 1,899.21 lakhs. Net loss widened to Rs 109.54 lakhs from Rs 92.30 lakhs in the previous year. Total expenses of Rs 2,063.30 lakhs exceeded total revenue of Rs 1,907.97 lakhs. The API segment generated Rs 1,893.58 lakhs in revenue with Rs 53.21 lakhs in result before interest and taxes. The Board approved these results on August 13, and auditors Gokhale & Sathe conducted a limited review.

Smruthi Organics

120.65

+0.20

(+0.17%)

1 Year Returns:0.00%

Industry Peers

Sun Pharmaceutical

1,872.70

(+1.34%)

Divis Laboratories

6,714.00

(+0.05%)

Torrent Pharmaceuticals

4,517.10

(+3.11%)

Dr Reddys Laboratories

1,279.90

(-1.08%)

Cipla

1,304.90

(-3.13%)

Lupin

2,255.90

(-5.19%)

Mankind Pharma

2,468.80

(+1.56%)

Zydus Life Science

956.95

(+1.80%)

Aurobindo Pharma

1,486.60

(-0.05%)

Laurus Labs

1,266.80

(+3.13%)

Get More Market Insights with

Stock Rental via SLBM

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104